2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.
Amrita Krishnan, MD, director, the Judy and Bernard Briskin Center for Multiple Myeloma, research professor, Department of Hematology and Hematopoietic Cell Transplantation, chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the effectiveness of teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma.
Data from the phase 1/2 MajestTEC-1 trial (NCT04557098) evaluated teclistamab vs patients in a real-world cohort.
Teclistamab elicited an improved progression-free survival, overall survival, and time to next therapy compared with to patients in the real-world database cohort, Krishnan explains, noting the limitations of a retrospective database study. Additional findings from the phase 1/2 MajestTEC-1 trial pointed to intriguing durability of responses in patients administered teclistamab, Krishnan says.
No new safety signals for teclistamab were reported on the trial, Krisnan adds. Infections continue to be an adverse effect to monitor with teclistamab, which is similar to other bispecific antibodies, Krishnan continues. It is important to bear in mind to optimize prophylaxis for those patients, Krishnan concludes.